The Characteristics and Outcomes of Patients with Heart Failure and Reduced Ejection Fraction: The Eligibility of Novel Heart Failure Medications.
Lists
Only you see this
Abstract
Approximately 70% and 63% of TSOC-HFrEF registry patients were ineligible for SAC/VAL and ivabradine, respectively, according to current TNHI regulations. Regardless of the eligibility for novel HFrEF medications, the high incidence of adverse events suggests that all patients should be treated cautiously.
BibTeX
@inproceedings{fong2021characteristics,
author = {Man Cai Fong and Hung Yu Chang and Chun Chieh Wang and An Ning Feng and Wei Lin and Yen‐Wen Wu and Shih Hsien Sung and Jin Huang and Jen Yuan Kuo and Wei Hsian Yin},
title = {{The Characteristics and Outcomes of Patients with Heart Failure and Reduced Ejection Fraction: The Eligibility of Novel Heart Failure Medications.}},
booktitle = {PubMed},
year = {2021},
doi = {10.6515/acs.202107\_37(4).20201223a},
}Loading related content...